Edgestream Partners L.P. Buys New Stake in Doximity, Inc. $DOCS

Edgestream Partners L.P. bought a new stake in Doximity, Inc. (NYSE:DOCS – Free Report) in the 3rd quarter, HoldingsChannel.com reports. The firm bought 244,390 shares of the company’s stock, valued at approximately $6,926,000.

Several other large investors have also recently made changes to their positions in the company. Carmignac Gestion boosted its holdings in Doximity by 127.8% during the first quarter. Carmignac Gestion now owns 4,311,997 shares of the company’s stock worth $100,480,000 after buying an additional 2,418,971 shares in the last quarter. Wellington Management Group LLP grew its position in Doximity by 24.7% during the second quarter. Wellington Management Group LLP now owns 3,135,113 shares of the company’s stock valued at $65,022,000 after buying an additional 621,464 shares during the period. Quantinno Capital Management LP grew its position in Doximity by 420.5% during the first quarter. Quantinno Capital Management LP now owns 140,345 shares of the company’s stock valued at $3,270,000 after buying an additional 113,380 shares during the period. Royal Bank of Canada increased its holdings in Doximity by 28.4% in the first quarter. Royal Bank of Canada now owns 206,282 shares of the company’s stock valued at $4,806,000 after buying an additional 45,618 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in Doximity in the third quarter valued at $28,858,000. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Doximity

In other news, CAO Siddharth Sitaram sold 2,613 shares of Doximity stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $30.68, for a total value of $80,166.84. Following the sale, the chief accounting officer owned 101,432 shares in the company, valued at $3,111,933.76. This trade represents a 2.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Watkin Phoebe L. Yang sold 1,290 shares of Doximity stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $26.71, for a total transaction of $34,455.90. Following the completion of the sale, the director owned 24,744 shares in the company, valued at approximately $660,912.24. This trade represents a 4.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 25,224 shares of company stock valued at $801,442. Insiders own 31.80% of the company’s stock.

Doximity Price Performance

Shares of NYSE:DOCS opened at $31.14 on Wednesday. Doximity, Inc. has a 1 year low of $17.15 and a 1 year high of $51.85. The firm has a market capitalization of $5.56 billion, a price-to-earnings ratio of 42.56, a price-to-earnings-growth ratio of 35.09 and a beta of 1.29. The business’s 50 day moving average price is $30.00 and its 200-day moving average price is $25.27.

Doximity (NYSE:DOCS – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.17. The firm had revenue of $174.54 million for the quarter. Doximity had a net margin of 21.12% and a return on equity of 15.80%. Doximity’s revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.45 EPS. On average, sell-side analysts expect that Doximity, Inc. will post 0.72 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $41.00 price objective on shares of Doximity in a research report on Friday, November 6th. Evercore set a $35.00 target price on shares of Doximity in a research note on Tuesday, September 29th. Wells Fargo & Company cut Doximity from an “equal weight” rating to an “underweight” rating and set a $18.00 target price on the stock. in a research report on Monday, August 10th. Royal Bank Of Canada lifted their price target on Doximity from $28.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, November 6th. Finally, Barclays lifted their price target on Doximity from $27.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 11th. Eight investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Doximity presently has a consensus rating of “Hold” and an average price target of $30.59.

Get Our Latest Research Report on DOCS

Doximity Profile

(Free Report)

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.

Featured Articles

Want to see what other hedge funds are holding DOCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Doximity, Inc. (NYSE:DOCS – Free Report).

Institutional Ownership by Quarter for Doximity (NYSE:DOCS)

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.